Condition: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis · Sponsor: Dynavax Technologies Corporation
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
This description comes directly from the study's public registry record.
Ouzama Henry, MD, Vice President, Clinical Development · 510-848-5100 · ohenry@dynavax.com
Always discuss trial participation with your own doctor first.
| 103 | Miami, Florida, United States | Active Not Recruiting |
| AMR- El Dorado | El Dorado, Kansas, United States | Active Not Recruiting |
| AMR- Las Vegas | Las Vegas, Nevada, United States | Active Not Recruiting |
| CTI Clinical Research Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07207408